Performance Comparison of Illumina® MiSeq™ and MiSeq™ i100 Systems using Invivoscribe’s LymphoTrack® Assays 2026-04-20T09:00:11-07:00May 27th, 2025| Read more
From prognostication to precision in acute myeloid leukemia 2025-05-08T16:47:49-07:00May 8th, 2025| Read more
Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML 2025-05-09T09:20:30-07:00May 8th, 2025| Read more
Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina® MiSeqTM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay 2026-01-07T13:13:14-08:00November 8th, 2024| Read more
Performance Comparison of Invivoscribe’s LymphoTrack® Assays Between Complete Genomics DNBSEQ-G99 and Illumina® MiSeqTM NGS Platforms 2026-04-20T09:02:18-07:00November 8th, 2024| Read more
EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA 2024-10-08T03:14:44-07:00October 8th, 2024| Read more
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML 2026-03-09T18:43:04-07:00May 8th, 2024| Read more
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA 2025-08-26T07:35:25-07:00July 21st, 2023| Read more
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research 2025-12-19T18:08:11-08:00June 2nd, 2023| Read more
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan 2025-12-29T12:29:29-08:00May 25th, 2023| Read more
The 30th Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer Jun 30 – Jul 2, 2026 Hiroshima, Japan Attending
